Original Article

CME Article: Rise in Neonatal Abstinence Syndrome Rate Is Associated with Increase in Buprenorphine Prescription Numbers

Authors: Summer Shore, BS, Nicole Lewis, PhD, Martin Olsen, MD

Abstract

Objectives: Southern Appalachia is a region of the United States that is disproportionately affected by the opioid epidemic and by increasing rates of neonatal abstinence syndrome (NAS). NAS rates increased approximately 400% between 1999 and 2012. Buprenorphine prescriptions written to treat opioid use disorder also increased dramatically. The present study was undertaken to ascertain any relationship between the number of buprenorphine prescriptions compared with NAS rates in southern Appalachia.

Methods: A total of 250 southern Appalachian counties across seven states, including all of West Virginia and portions of Virginia, Kentucky, Maryland, North Carolina, Ohio, and Tennessee were identified. A retrospective cohort analysis of these counties was conducted for the years 2005–2018. All of the data were obtained from publicly accessible sources or direct communication with government offices. Measures from each county in southern Appalachia included annual NAS rates, buprenorphine prescription rates, drug-induced death rates, and opioid prescribing rates. Associations among these variables were examined using a generalized linear regression.

Results: Significant linear associations exist between the rising rate of NAS diagnoses and the rising rate of buprenorphine prescriptions (r = 0.977, R2 = 95.53%, P < 0.001) and between the rising rate of buprenorphine prescriptions and the increase in drug-induced deaths (r = 0.712, R2 = 50.82%, P = 0.031).

Conclusions: This is the first report that documents an association between rising NAS rates and increasing buprenorphine prescribing. Between the years 2010 and 2018, the NAS rate in southern Appalachia rose by 335%, and the number of buprenorphine prescriptions rose by 413%. Discussions regarding the current policies for buprenorphine management during pregnancy are warranted. We suggest a reevaluation of buprenorphine prescribing recommendations during pregnancy and further research on establishing the lowest effective buprenorphine dose for each pregnant patient.
Posted in: Pregnancy32

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000- 2009. JAMA 2012;307:1934–1940.
 
2. Strahan AE, Guy GP, Bohm M, et al. Neonatal abstinence syndrome incidence and health care costs in the United States, 2016. JAMA Pediatr 2020;174:200–202.
 
3. Brown JD, Doshi PA, Pauly NJ, et al. Rates of neonatal abstinence syndrome amid efforts to combat the opioid abuse epidemic. JAMA Pediatr 2016;170: 1110–1112.
 
4. Jilani SM, Frey MT, Pepin D, et al. Evaluation of state-mandated reporting of neonatal abstinence syndrome—six states, 2013–2017. MMWR Morb Mortal Wkly Rep 2019;68;6–10.
 
5. Centers for Disease Control and Prevention. Data and statistics about opioid use during pregnancy. https://www.cdc.gov/pregnancy/opioids/data.html. Accessed March 15, 2023.
 
6. Fill MA, Miller AM, Wilkinson RH, et al. Educational disabilities among children born with neonatal abstinence syndrome. Pediatrics 2018;142: e20180562.
 
7. Garrison-Desany HM, Hong X, Maher BS, et al. Individual and combined association between prenatal polysubstance exposure and childhood risk of attention-deficit/hyperactivity disorder. JAMA Netw Open 2022;5:e221957.
 
8. Towers CV, Hyatt BW, Visconti KC, et al. Neonatal head circumference in newborns with neonatal abstinence syndrome. Pediatrics 2019;143: e20180541.
 
9. Caritis SN, Panigrahy A. Opioids affect the fetal brain: reframing the detoxification debate. Am J Obstet Gynecol 2019;221:602–608.
 
10. Ashraf K, Zahra A, Zohre K. Relationship between mindfulness and maternal stress and mother – infant bonding in neonatal intensive care unit. J Edu Health Promot 2021;10:337.
 
11. Rockefeller K, Macken LC, Craig A. Trying to do what is best: a qualitative study of maternal-infant bonding and neonatal abstinence syndrome. Adv Neonatal Care 2019;19:E3–E15.
 
12. Nyakeriga AM, McDonald M. Neonatal abstinence syndrome surveillance annual report 2020. https://www.tn.gov/content/dam/tn/health/documents/nas/NAS-Annual-Report-2020.pdf. Published 2020. Accessed January 23, 2023.
 
13. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP) Fast Stats. https://datatools.ahrq.gov/hcup-fast-stats/. Accessed August 2, 2021.
 
14. Tennessee Department of Health. Tennessee drug overdose dashboard. https://www.tn.gov/health/health-program-areas/pdo/pdo/data-dashboard.html. Accessed January 23, 2023.
 
15. Tennessee Department of Health. Neonatal abstinence syndrome surveillance, May 2019 update (data through 06/01/2019). https://www.tn.gov/content/dam/tn/health/documents/nas/May_2019__NAS_Monthly_Update.pdf. Accessed January 2, 2023.
 
16. Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med 2019; 13:93–103.
 
17. US Department of Health & Human Services, Substance Abuse and Mental Health Treatment Services Administration. Medications for substance use disorders. https://www.samhsa.gov/medications-substance-use-disorders. Accessed January 23, 2023.
 
18. US Food and Drug Administration. Information about medication-assisted treatment (MAT). https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat. Published 2019. Accessed March 14, 2023.
 
19. US Department of Health & Human Services, Substance Abuse and Mental Health Treatment Services Administration. Methadone. https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/methadone. Accessed January 23, 2023.
 
20. Duff JH. Buprenorphine and the opioid crisis: a primer for Congress. https://crsreports.congress.gov/product/pdf/R/R45279/5. Published December 7, 2018. Accessed January 23, 2023.
 
21. American College of Emergency Physicians. Biden administration finalizes buprenorphine practice guidelines: a step in the right direction. https://www.acep.org/federal-advocacy/federal-advocacy-overview/regs--eggs/regs--eggs-articles/regs--eggs---april-29-2021. Published April 29, 2021. Accessed January 23, 2023.
 
22. Han B, Jones CM, Einstein EB, et al. Trends in and characteristics of buprenorphine misuse among adults in the US. JAMA Netw Open 2021;4: e2129409.
 
23. Lavonas EJ, Severtson SG, Martinez EM, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat 2014;47:27–34.
 
24. Johanson CE, Arfken CL, di Menza S, et al. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012;120:190–195.
 
25. Hӓkkinen M, Heikman P, Ojanperӓ I. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning. Forensic Sci Int 2013;232:11–15.
 
26. Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend 2018;193:117–123.
 
27. Barsky BA, Busch AB, Patel SY, et al. Use of telemedicine for buprenorphine inductions in patients with commercial insurance or Medicare Advantage. JAMA Netw Open 2022;5:e2142531.
 
28. Wang L,Weiss J, Ryan EB, et al. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. Subst Abuse Treat 2021;124:108272.
 
29. Alexander C, Breuel K, Olsen M. High prevalence of buprenorphine in prenatal drug screens in an Appalachian city. South Med J 2020;113:111–115.
 
30. Erwin PC, Meschke LL, Ehrlich SF, et al. Neonatal abstinence syndrome in east Tennessee: characteristics and risk factors among mothers and infants in one area of Appalachia. J Health Care Poor Underserved 2017;28: 1393–1408.
 
31. Centers for Disease Control and Prevention. Module 6: dosing and titration of opioids: how much, how long, and how and when to stop? https://www.cdc.gov/drugoverdose/training/dosing/accessible/index.html. Accessed January 23, 2023.
 
32. Appalachian Regional Commission. Appalachian counties served by ARC. https://www.arc.gov/Appalachian-counties-served-by-arc. January 23, 2023.
 
33. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. WISQARSTM — Web-Based Injury Statistics Query and Reporting System. https://www.cdc.gov/injury/wisqars/. Accessed August 6, 2021.
 
34. McNeer E, Patrick SW, Faherty LJ, et al. Simulation of county neonatal abstinence syndrome (NAS) rates tool. https://www.rand.org/pubs/tools/TL327.html. Published 2019. Accessed January 23, 2023.
 
35. US Department of Health and Human Services, Maternal and Child Health Bureau. National outcome measures 11: neonatal abstinence syndrome. https://mchb.tvisdata.hrsa.gov/PrioritiesAndMeasures/NationalOutcomeMeasures. Accessed January 24, 2023.
 
36. Virginia Department of Health. Neonatal abstinence syndrome (NAS). https://www.vdh.virginia.gov/drug-overdose-data/neonatal-abstinence-syndrome-nas/. Accessed January 24, 2023.
 
37. North Carolina Department of Health and Human Services. Opioid and substance use action plan data dashboard. https://www.ncdhhs.gov/opioid-and-substance-use-action-plan-data-dashboard. Accessed June 15, 2021.
 
38. Ohio Automated Rx Reporting System. Stats: PDMP interactive data tool. https://www.ohiopmp.gov/Stats. Accessed June 15, 2021.
 
39. Kentucky Safety and Prevention Alignment Network. Annual KASPER threshold analysis report 2015, annual KASPER threshold analysis report 2016, and KASPER quarterly threshold reports 2017. https://www.safekentucky.org/index.php/menu-drug-abuse/kasper-reports. Accessed January 24, 2023.
 
40. Centers for Disease Control and Prevention. U.S. opioid dispensing rate maps (2006–2019. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html. Accessed January 24, 2023
 
41. Centers for Disease Control and Prevention. Calculating total daily dose of opioids for safer dosage. https://www.cdc.gov/opioids/providers/prescribing/pdf/calculating-total-daily-dose.pdf. Accessed January 24, 2023.
 
42. Highlights of prescribing information—Subutex. https://www.accessdata.fda. gov/drugsatfda_docs/label/2018/020732s018lbl.pdf. Published February 2018. Accessed January 2, 2023.
 
43. Food and Drug Administration. FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and price trends. https://www.fda.gov/files/about%20fda/published/FDA-Analysis-of-Long-Term-Trends-in-Prescription-Opioid-Analgesic-Products--Quantity--Sales--and-Price-Trends.pdf. Accessed January 11, 2023.
 
44. O’Connor AB, O’Brien L, Alto WA. Maternal buprenorphine dose at delivery and its relationship to neonatal outcomes. Eur Addict Res 2016;22:127–130.
 
45. Brogly SB, Saia KE, Werler MM, et al. 2018). Prenatal Treatment and Outcomes of Women With Opioid Use Disorder. Obstet Gynecol 2018;132:916–922.
 
46. Ostrea EM Jr, Chavez CJ, Strauss ME. A study of factors that influence the severity of neonatal narcotic withdrawal. Addict Dis 1975;2:187–199.
 
47. Madden JD, Chappel JN, Zuspan F, et al. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol 1977;127:199–201.
 
48. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991;118:933–937.
 
49. Harper RG, Solish G, Feingold E, et al. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977;129:417–424.
 
50. Malpas TJ, Darlow BA, Lennox R, et al. Maternal methadone dosage and neonatal withdrawal. Aust N Z J Obstet Gynaecol 1995;25:175–177.
 
51. Chilcoat HD, Amick HR, Sherwood MR, et al. Buprenorphine in the United States: motives for abuse, misuse, and diversion. J Subst Abuse Treat 2019; 104:148–157.
 
52. Buttram ME, Kurtz SP, Margolin ZR, et al. Increasing rates of buprenorphine diversion in the United States, 2002 to 2019. Pharmacoepidemiol Drug Saf 2021;30:1514–1519.
 
53. Carlson RG, Daniulaityte R, Silverstein SM, et al. Unintentional drug overdose: is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose? Int J Drug Policy 2020;79:102722.
 
54. del Pozo B, Krasner LS, George SF. Decriminalization of diverted buprenorphine in Burlington, Vermont and Philadelphia: an intervention to reduce opioid overdose deaths. J Law Med Ethics 2020;48:373–375.
 
55. Li X, Shorter D, Kosten TR. Buprenorphine prescribing: to expand or not to expand. J Psychiatr Pract 2016;22:183–192.
 
56. Volkow ND, Jones EB, Einstein EB, et al. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 2019;76:208–216.
 
57. Savage C. The New York Times in Education. Biden administration offers plan to get addiction-fighting medicine to pregnant women. https://nytimesineducation.com/biden-administration-offers-plan-to-get-addiction-fighting-medicine-to-pregnant-women/. Published October 25, 2022. Accessed October 25, 2022.